Johnson & Johnson profit dives 35% as coronavirus zaps sales of beauty products, medical devices
Medical device sales plunged 34%
Johnson & Johnson CFO Joe Wolk on beating second-quarter earnings estimates and the development of a coronavirus vaccine.
Johnson & Johnson’s second-quarter profit slumped 35 percent from a year ago as COVID-19 slowed demand for beauty products and medical devices.
The New Brunswick, New Jersey-based healthcare products manufacturer earned $3.63 billion, or an adjusted $1.67 a share, as revenue slid 10.8 percent year-over-year to $18.3 billion. Wall Street analysts surveyed by Refinitiv were anticipating adjusted earnings of $1.49 a share on sales of $17.6 billion.
STOCKS JUMP ON CORONAVIRUS VACCINE HOPES
Consumer health sales fell 7 percent from a year ago to $3.3 billion as consumers bought fewer skin health and beauty products while sheltering at home during the COVID-19 pandemic. Medical device sales tumbled 34 percent to $4.29 billion as elective surgeries were put on hold.
"Our second-quarter results reflect the impact of COVID-19 and the enduring strength of our pharmaceutical business, where we saw continued growth even in this environment," CEO Alex Gorsky said in a statement.
Johnson & Johnson Executive Committee Vice Chairman Dr. Paul Stoffels discusses speeding up coronavirus vaccine development and scaling up distribution.
Pharmaceuticals sales, which accounted for 59 percent of revenue, were the lone bright spot, climbing 2.1 percent from a year ago to $10.75 billion.
Looking ahead, Johnson & Johnson sees full-year adjusted earnings of $7.75 to $7.95 a share, up from its April forecast of $7.50 to $7.90. The company also projects full-year adjusted operational sales will slip as much as 0.8 percent or climb as much as 1 percent.
CLICK HERE TO READ MORE ON FOX BUSINESS
Johnson & Johnson shares gained 1.63 percent year-to-date through Wednesday, outperforming the S&P 500's 1.3 percent decline.